Ingenuity Systems and Agilent Technologies to Offer Interoperbility in Bioinformatics Software
Ingenuity Systems and Agilent Technologies, Inc. today announced an agreement to establish integration between Agilent’s GeneSpring Analysis Platform and Ingenuity Pathways Analysis. Genomics researchers will be able to easily exchange data between both applications, leveraging each system’s ability to analyze high-volume gene expression data and to perform advanced biological pathway analysis.
“GeneSpring is designed to answer biological questions at the intersection of genomics, genetics, proteomics and biomarker screening,” said Jordan Stockton, Agilent Informatics marketing manager. “The integration with Ingenuity Pathways Analysis also supports our mutual customers by providing rigorous statistical analysis, followed immediately by a comprehensive exploration of relevant biological pathways. Ultimately, our users can address a more complete range of research questions.”
“By integrating the Ingenuity Pathway Analysis solution with GeneSpring, our joint customers will have greater flexibility and bandwidth for analyzing and accessing their gene expression data,” said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems. “This collaboration is part of our strategy to seamlessly integrate Ingenuity Pathways Analysis into the natural workflow of our customers, allowing them to uncover mechanisms of action, predict potential toxicities and give biological meaning to their gene expression data with internal or third-party tools.”
About Agilent’s GeneSpring
Agilent’s GeneSpring Analysis Platform integrates data and results from multiple measurement technologies. GeneSpring provides comprehensive statistical analysis, data mining and visualization tools that have been used in a wide range of research applications, including those cited in more than 1,100 peer-reviewed articles in leading scientific publications. Designed to meet the needs of the individual researcher and the global enterprise, GeneSpring provides a highly scalable environment for genomic research. Agilent develops, supports and exclusively distributes this software.
About Ingenuity’s IPA
Ingenuity Pathways Analysis is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at www.ingenuity.com/trial .
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 20,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.1 billion in fiscal 2005. Information about Agilent is available on the Web at www.agilent.com .
About Ingenuity Systems
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom and Japan. For more information, visit www.ingenuity.com
